Inscrivez-vous pour créer des alertes relatives aux instruments,
aux événements économiques et au contenu publié par vos auteurs préférés
Inscription gratuite Vous avez déjà un compte ? Connexion
34,52
-0,82
-2,32%
Cotations
Tous types d’instruments
- Tous types d’instruments
- Indices
- Actions
- ETF
- Fonds
- Mat. prem.
- Devises
- Crypto
- Oblig.
- Certificats
Merci d'essayer une autre recherche
🐂 La sélection d'actions ProPicks AI de novembre inclut déjà 5 gains de plus de 20% chacun
Voir les actions
Eventide Healthcare & Life Sciences Fund Class A Shares (ETAHX)
Ajouter au/Supprimer du portefeuille
Ajout au Portefeuille
14/11 - En Différé. Devise en USD
- Rating de Morningstar:
- Actif total: 119,06M
Eventide Healthcare & Life Sciences A
34,52
-0,82
-2,32%
Vue d'ensemble ETAHX
Sur cette page vous trouverez un profil détaillé de Eventide Healthcare & Life Sciences Fund Class A Shares. Vous y trouverez notamment des informations sur la gestion, le total des actifs, la stratégie d'investissement et les coordonnées de ETAHX entre autres informations.
Contact
Principaux dirigeants
| Nom | Titre | Depuis | Jusqu’à |
|---|---|---|---|
| I-hung Shih | Portfolio Manager | 2024 | Maintenant |
| Biographie | I-hung Shih, PhD, Biochemistry, joined Eventide in July 2024 and has led Eventide’s Healthcare team as Managing Director and Co-Portfolio Manager since September 2024 under the supervision of the Adviser’s Co-Chief Investment Officers. Effective September 1, 2024, Dr. Shih will be a Managing Director for Eventide Ventures®, Eventide's private investing line of business. Dr. Shih has over 20 years of professional experience. Before starting at Eventide she was Portfolio Manager and a Global Industry Analyst before being promoted as Co-Head of Wellington Biotech Private Investments at Wellington Management Company. Prior to her time at Wellington, Dr. Shih held investment management roles on teams at T.Rowe Price, Temasek International, and Credit Suisse. She began her career in research, working as a Research Fellow at the NIH and Whitehead Institute at MIT. Following those experiences, she joined Gilead Sciences where she started as a Research Scientist, and then worked as a Senior Manager in Commercial Strategy, before entering the investment management industry. Dr. Shih holds a PhD in Biochemistry from Duke University. She also holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Chemistry from the National Taiwan University. | ||
| Finny Kuruvilla | Resident | 2012 | Maintenant |
| Biographie | Finny Kuruvilla, MD, PhD, serves as a Co-Chief Investment Officer, Senior Portfolio Manager for Eventide’s mid-cap growth and healthcare & life sciences strategies, a Managing Director for Eventide’s private fund, as well as Founding Member of Eventide. Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech. | ||
| Kyle Rasbach | Portfolio Manager | 2023 | 2024 |
| Biographie | Kyle Rasbach, PhD, PharmD, joined Eventide in April 2022, and has led Eventide’s Healthcare team across all Eventide Investment products since June 2022 under the supervision of the Adviser’s Co-Chief Investment Officers. Dr. Rasbach has served as a Managing Director for the Eventide Healthcare Innovation Fund I, LP, since November 2022. Dr. Rasbach has extensive experience in clinical pharmacology, basic science, and healthcare equity research. Prior to joining Eventide, Dr. Rasbach was a Managing Partner at Pappas Capital, a life science venture capital firm that invests across biotechnology, biopharmaceuticals, drug delivery, and medical devices, from 2017-2022. Earlier in his career he was an equity research analyst and Vice President at T. Rowe Price from 2013-2017, where he managed pharmaceutical, specialty pharmaceutical, and biotechnology investments. Prior to joining T. Rowe Price, Dr. Rasbach was an equity research associate and Vice President at Cowen and Company from 2010-2013, where he covered global pharmaceutical equities. Dr. Rasbach holds a PhD in Pharmaceutical and Biomedical Sciences as well as a PharmD from the Medical University of South Carolina; he completed his postdoctoral training in the laboratory of Bruce Spiegelman at the Harvard Medical School. He also holds an MBA from The Citadel and a BS in Biology from Denison University. | ||
| Joy Ghosh | Portfolio Manager | 2022 | 2022 |
| Biographie | Dr. Joy Ghosh has served the Adviser as a Portfolio Manager since January 2022 and Senior Analyst since 2020. Prior to joining the Adviser, Dr. Ghosh was Vice President of Bain Capital from 2019 to 2020 and an Associate of Bain Capital from 2017 to 2019. Dr. Ghosh holds a PhD from the University of Washington, Seattle in Biomolecular Structure and Design and a bachelor’s degree in Biochemistry from the University of Texas at Austin. | ||
Exprimez-vous à propos de Eventide Healthcare & Life Sciences Fund Class A Shares
Êtes-vous sûr de vouloir supprimer ce graphique ?
Supprimer Annuler
Remplacer le graphique actuel par un nouveau graphique?
Remplacer Annuler
Charte de discussion
Ajouter un graphique au commentaire
Confirmer le blocage
Voulez-vous vraiment bloquer %USER_NAME% ?
Si vous continuez, vous et %USER_NAME% ne verrez plus vos publications Investing.com mutuelles.
%USER_NAME% a bien été ajouté à votre Liste d’utilisateurs bloqués
Vous venez de débloquer cette personne et devrez attendre 48 heures avant de la bloquer de nouveau.
Signaler ce commentaire comme inapproprié
Je souhaite signaler ce commentaire comme:
Commentaire signalé
Merci
Le commentaire signalé sera révisé par nos modérateurs